Cargando…

Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?

Radical cystectomy (RC) is the standard of care treatment of localized muscle-invasive bladder cancer (BC). However, about 50% of patients develop metastases within 2 years after cystectomy. Neoadjuvant cisplatin-based chemotherapy before cystectomy improves the overall survival (OS) in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wezel, Felix, Vallo, Stefan, Roghmann, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760384/ https://www.ncbi.nlm.nih.gov/pubmed/29354494 http://dx.doi.org/10.21037/tau.2017.09.18

Ejemplares similares

KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer
por: Jütte, Hendrik, et al.
Publicado: (2021)

Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy
por: Sui, Wilson, et al.
Publicado: (2017)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy for Advanced Gallbladder Cancer: Do We have Enough Evidence? A Systematic Review
por: Naveed, Shah, et al.
Publicado: (2021)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
por: Eldefrawy, Ahmed, et al.
Publicado: (2012)

Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer
por: Sawasdee, Anupong, et al.
Publicado: (2022)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
por: Meghal, Trishala, et al.
Publicado: (2019)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Neoadjuvant and Adjuvant Chemotherapy for Variant Histology Bladder Cancers: A Systematic Review and Meta-Analysis
por: Zhu, Ziwei, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Invasive Bladder Cancer
por: Oliver, R.T.D.
Publicado: (1991)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
por: Del Bene, Gabriella, et al.
Publicado: (2018)

Stem Cell Therapy in Bladder Dysfunction: Where Are We? And Where Do We Have to Go?
por: Kim, Jae Heon, et al.
Publicado: (2013)

NEO adjuvant chemotherapy in breast cancer: What have we learned so far?
por: Raut, Nirmal V, et al.
Publicado: (2010)

Anaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy
por: Groenewold, M.D., et al.
Publicado: (2022)

Adjuvant chemotherapy in patients with locally advanced bladder cancer after neoadjuvant chemotherapy and radical cystectomy: a systematic review and pooled analysis
por: Cai, Zhiyong, et al.
Publicado: (2021)

Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature
por: Oneda, Ester, et al.
Publicado: (2019)

Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?
por: Lima, Luís, et al.
Publicado: (2012)

Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?
por: Pérez-García, José, et al.
Publicado: (2012)

Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease?
por: Zabell, Joseph, et al.
Publicado: (2018)

Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts
por: Vallo, Stefan, et al.
Publicado: (2016)

Rectal cancer patients with downstaging after neoadjuvant chemoradiotherapy and radical resection do not benefit from adjuvant chemotherapy
por: Zhang, Hang, et al.
Publicado: (2020)

The present and future of non-muscle invasive bladder cancer
por: Moschini, Marco, et al.
Publicado: (2019)

Oxidative damage to DNA: do we have a reliable biomarker?
por: Collins, A R, et al.
Publicado: (1996)

Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologist’s Perspective
por: Park, Sehhoon
Publicado: (2023)

Do We Have the Spark?
por: Rupel, Valentina Prevolnik, et al.
Publicado: (2022)

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Miyagi, Hiroko, et al.
Publicado: (2022)

Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer?
por: Kleeff, Jörg, et al.
Publicado: (2019)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
por: España Fernandez, Sofia, et al.
Publicado: (2023)

Abstract 11. The Effect of Neoadjuvant Chemotherapy Compared to Adjuvant Chemotherapy in Nipple-Sparing Mastectomy
por: Frey, Jordan D., et al.
Publicado: (2017)

The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy
por: Li, Keting, et al.
Publicado: (2023)

Capecitabine Induced Multifocal Leukoencephalopathy: Do We Have Always to Switch off the Chemotherapy?
por: Bougea, Anastasia, et al.
Publicado: (2016)

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
por: Sun, Jong-Mu, et al.
Publicado: (2012)

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
por: Shukla, Nikhil, et al.
Publicado: (2021)

Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer
por: Lin, Guang-Tan, et al.
Publicado: (2022)

Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?
por: Chau, Brittney, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ej4k3bst7p8emgln1hlbbnfcjm